
|Articles|March 1, 2004
Etanercept shows safety, efficacy through five years
Washington -- A new study presented in poster form at the recent AAD meeting concludes that etanercept continues to post an excellent record for the treatment of rheumatoid arthritis. The drug maintains its safety profile and clinical efficacy for treatment durations of more than five years.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
JAK Inhibitors Show Comparable Safety to TNF Antagonists
3
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















